Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

ClinicalTrials.gov ID: NCT02408523

Public ClinicalTrials.gov record NCT02408523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy

Study identification

NCT ID
NCT02408523
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Enrollment
242 participants

Conditions and interventions

Conditions

Interventions

  • Lacosamide Tablet Drug
  • Lasosamide Oral Solution Drug
  • Placebo Tablet Other
  • Placebo Oral Solution Other

Drug · Other

Eligibility (public fields only)

Age range
4 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2015
Primary completion
Mar 31, 2019
Completion
May 31, 2019
Last update posted
Dec 16, 2020

2015 – 2019

United States locations

U.S. sites
27
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Sp0982 028 Alabaster Alabama 35007
Sp0982 005 Little Rock Arkansas 72205
Sp0982 018 Irvine California 92868
Sp0982 008 Santa Monica California 90404
Sp0982 031 Colorado Springs Colorado 80910
Sp0982 035 Denver Colorado 80202
Sp0982 036 Danbury Connecticut 06810
Sp0982 011 Jacksonville Florida 32224
Sp0982 013 Panama City Florida 32405
Sp0982 002 Port Charlotte Florida 33952
Sp0982 042 Wellington Florida 33470
Sp0982 015 Boise Idaho 83702
Sp0982 021 Peoria Illinois 61637
Sp0982 045 Springfield Illinois 62702
Sp0982 009 New Orleans Louisiana 70121
Sp0982 007 Bethesda Maryland 20817
Sp0982 010 Waldorf Maryland 20603
Sp0982 025 Golden Valley Minnesota 55422
Sp0982 029 St Louis Missouri 63131
Sp0982 043 New York New York 10016
Sp0982 053 Austin Texas 78758
Sp0982 050 Greenville Texas 75401
Sp0982 034 Houston Texas 77025
Sp0982 047 San Antonio Texas 78207
Sp0982 038 San Antonio Texas 78229
Sp0982 027 Renton Washington 98057
Sp0982 023 Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02408523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02408523 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →